Best Buy Stocks [LATEST]

: Up over 204% YTD following successful Phase 3 trials for its psoriasis therapy.

: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments. best buy stocks

: Up 301% YTD as of April 2026. It is currently the top performer in the S&P 500, benefiting from soaring demand for NAND flash memory used in AI data centers. : Up over 204% YTD following successful Phase

Several companies have seen triple-digit gains in the first four months of 2026, often led by specialized healthcare breakthroughs or critical AI hardware components. It is currently the top performer in the

: Up roughly 394% YTD following the commercial launch of its cancer therapy, Anktiva, in Saudi Arabia and expansion into Europe.

: Up over 115% YTD (as of April 27) following a recent 21% surge and bullish outlook on its manufacturing turnaround. Analyst "Best Buy" Recommendations for 2026